These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 8764622)

  • 1. Isoniazid-related fatal hepatitis.
    Millard PS; Wilcosky TC; Reade-Christopher SJ; Weber DJ
    West J Med; 1996 Jun; 164(6):486-91. PubMed ID: 8764622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic.
    Nolan CM; Goldberg SV; Buskin SE
    JAMA; 1999 Mar; 281(11):1014-8. PubMed ID: 10086436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana.
    Tedla Z; Nyirenda S; Peeler C; Agizew T; Sibanda T; Motsamai O; Vernon A; Wells CD; Samandari T
    Am J Respir Crit Care Med; 2010 Jul; 182(2):278-85. PubMed ID: 20378730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis.
    Salpeter SR; Sanders GD; Salpeter EE; Owens DK
    Ann Intern Med; 1997 Dec; 127(12):1051-61. PubMed ID: 9412307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis.
    Salpeter SR
    West J Med; 1993 Nov; 159(5):560-4. PubMed ID: 8279152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isoniazid-associated hepatitis in adults infected with HIV receiving 36 months of isoniazid prophylaxis in Botswana.
    Tedla Z; Nguyen ML; Sibanda T; Nyirenda S; Agizew TB; Girde S; Rose CE; Samandari T
    Chest; 2015 May; 147(5):1376-1384. PubMed ID: 25340318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of long-term isoniazid preventive therapy in children with HIV: a comparison of two dosing schedules.
    le Roux SM; Cotton MF; Myer L; le Roux DM; Schaaf HS; Lombard CJ; Zar HJ
    Int J Tuberc Lung Dis; 2013 Jan; 17(1):26-31. PubMed ID: 23146410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isoniazid-induced acute liver failure during preventive therapy for latent tuberculosis infection.
    Miyazawa S; Matsuoka S; Hamana S; Nagai S; Nakamura H; Nirei K; Moriyama M
    Intern Med; 2015; 54(6):591-5. PubMed ID: 25786447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe isoniazid-associated hepatitis--New York, 1991-1993.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1993 Jul; 42(28):545-7. PubMed ID: 8326947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isoniazid-related hepatic failure in children: a survey of liver transplantation centers.
    Wu SS; Chao CS; Vargas JH; Sharp HL; Martín MG; McDiarmid SV; Sinatra FR; Ament ME
    Transplantation; 2007 Jul; 84(2):173-9. PubMed ID: 17667808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection.
    Gray EL; Goldberg HF
    Intern Med J; 2016 Mar; 46(3):281-7. PubMed ID: 26648478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study.
    Kopanoff DE; Snider DE; Caras GJ
    Am Rev Respir Dis; 1978 Jun; 117(6):991-1001. PubMed ID: 666111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From the Centers for Disease Control and Prevention. Severe isoniazid-associated hepatitis--New York, 1991-1993.
    JAMA; 1993 Aug; 270(7):809. PubMed ID: 8340970
    [No Abstract]   [Full Text] [Related]  

  • 14. Assessment of age-related isoniazid hepatotoxicity during treatment of latent tuberculosis infection.
    Aziz H; Shubair M; Debari VA; Ismail M; Khan MA
    Curr Med Res Opin; 2006 Jan; 22(1):217-21. PubMed ID: 16393447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity.
    Hayashi PH; Fontana RJ; Chalasani NP; Stolz AA; Talwalkar JA; Navarro VJ; Lee WM; Davern TJ; Kleiner DE; Gu J; Hoofnagle JH;
    Clin Gastroenterol Hepatol; 2015 Sep; 13(9):1676-82.e1. PubMed ID: 25724701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States.
    Patel PA; Voigt MD
    Am J Gastroenterol; 2002 May; 97(5):1198-203. PubMed ID: 12014728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isoniazid-induced acute hepatitis and acute pancreatitis in a patient during chemoprophylaxis.
    Jin CF; Sable R
    J Clin Gastroenterol; 2002 Jul; 35(1):100-1. PubMed ID: 12080238
    [No Abstract]   [Full Text] [Related]  

  • 18. [Secular increase in the incidence rate of drug-induced hepatitis due to anti-tuberculosis chemotherapy including isoniazid and rifampicin].
    Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H; Mohri M
    Kekkaku; 2003 Apr; 78(4):339-46. PubMed ID: 12739393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.
    Lee BH; Koh WJ; Choi MS; Suh GY; Chung MP; Kim H; Kwon OJ
    Chest; 2005 Apr; 127(4):1304-11. PubMed ID: 15821209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The age threshold for isoniazid chemoprophylaxis. A decision analysis for low-risk tuberculin reactors.
    Rose DN; Schechter CB; Silver AL
    JAMA; 1986 Nov; 256(19):2709-13. PubMed ID: 3773178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.